Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase

被引:636
作者
Jaiswal, RK
Jaiswal, N
Bruder, SP
Mbalaviele, G
Marshak, DR
Pittenger, MF
机构
[1] Osiris Therapeut Inc, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA
关键词
D O I
10.1074/jbc.275.13.9645
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Adult human mesenchymal stem cells are primary, multipotent cells capable of differentiating to osteocytic, chondrocytic, and adipocytic lineages when stimulated under appropriate conditions. To characterize the molecular mechanisms that regulate osteogenic differentiation, we examined the contribution of mitogen-activated protein kinase family members, ERK, JNK, and p38, Treatment of these stem cells with osteogenic supplements resulted in a sustained phase of ERK activation from day 7 to day 11 that coincided with differentiation, before decreasing to basal levels. Activation of JNK occurred much later (day 13 to day 17) in the osteogenic differentiation process. This JNK activation was associated with extracellular matrix synthesis and increased calcium deposition, the two hallmarks of bone formation. Inhibition of ERK activation by PD98059, a specific inhibitor of the ERK signaling pathway, blocked the osteogenic differentiation in a dose-dependent manner, as did transfection with a dominant negative form of MAP kinase kinase (MEK-1), Significantly, the blockage of osteogenic differentiation resulted in the adipogenic differentiation of the stem cells and the expression of adipose-specific mRNAs peroxisome proliferator-activated receptor gamma 2, aP2, and lipoprotein lipase. These observations provide a potential mechanism involving MAP kinase activation in osteogenic differentiation of adult stem cells and suggest that commitment of hMSCs into osteogenic or adipogenic lineages is governed by activation or inhibition of ERK, respectively.
引用
收藏
页码:9645 / 9652
页数:8
相关论文
共 64 条
  • [1] Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site
    Adams, M
    Reginato, MJ
    Shao, DL
    Lazar, MA
    Chatterjee, VK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (08) : 5128 - 5132
  • [2] PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO
    ALESSI, DR
    CUENDA, A
    COHEN, P
    DUDLEY, DT
    SALTIEL, AR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) : 27489 - 27494
  • [3] BERESFORD JN, 1992, J CELL SCI, V102, P341
  • [4] CHARACTERIZATION OF DIFFERENTIATION FACTOR LEUKEMIA INHIBITORY FACTOR EFFECT ON LIPOPROTEIN-LIPASE ACTIVITY AND MESSENGER-RNA IN 3T3-L1 ADIPOCYTES
    BERG, M
    FRAKER, DL
    ALEXANDER, HR
    [J]. CYTOKINE, 1994, 6 (04) : 425 - 432
  • [5] Blanque R, 1997, DRUG EXP CLIN RES, V23, P63
  • [6] SIGNAL-TRANSDUCTION VIA THE MAP KINASES - PROCEED AT YOUR OWN RSK
    BLENIS, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (13) : 5889 - 5892
  • [7] Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO
  • [8] 2-F
  • [9] MESENCHYMAL STEM-CELLS IN IN BONE-DEVELOPMENT, BONE REPAIR, AND SKELETAL REGENERATION THERAPY
    BRUDER, SP
    FINK, DJ
    CAPLAN, AI
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, 56 (03) : 283 - 294
  • [10] Bruder SP, 1998, CLIN ORTHOP RELAT R, pS247